Author: Willem van Lawick

– Results from the single dose 1-year follow up consistent with prior Phase II study – Data supports already submitted marketing authorization application Amsterdam-Duivendrecht, The Netherlands, January 31, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell therapy products aiming to… Continue reading Last patient dosed with ATIR101™ in the Phase II ‘008’ clinical trial

Amsterdam-Duivendrecht, The Netherlands, January 16, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell therapy products to make bone marrow transplantations safer and more effective for patients, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory… Continue reading Kiadis Pharma proposes former Cipla CEO Subhanu Saxena as new Supervisory Board member

Amsterdam-Duivendrecht, The Netherlands, December 6, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell therapy products to make bone marrow transplantations safer and more effective for patients, today announces that it has entered into an agreement to lease an existing commercial… Continue reading Kiadis Pharma to lease existing commercial manufacturing facility in The Netherlands

Amsterdam-Duivendrecht, The Netherlands, December 4, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell-therapy products to make bone marrow transplantations safer and more effective for patients, today announces that the first patient has been enrolled in the HATCY Phase 3 clinical… Continue reading First patient enrolled in Phase 3 trial for ATIR101™ in adult patients with blood cancer

Amsterdam-Duivendrecht, The Netherlands, October 10, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that it has raised gross proceeds… Continue reading Kiadis Pharma raises €18.0 million in a private placement of 2.25 million new shares